-
1.发明授权3,4-DIAMINO-6-CHLOROPYRAZINE-2-CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF ENAC MEDIATED DISEASES 有权3,4-二氨基-6-氯吡嗪-2-羧酰胺类化合物用于治疗ENAC介导的疾病
公开(公告)号：EP3119752B1
公开(公告)日：2018-05-16
申请号：EP15713339.8
申请日：2015-03-17
申请人： Astrazeneca AB
发明人： BERGLUND, Susanne, Elisabeth , CONNOLLY, Stephen , HEMMERLING, Martin , HOSSAIN, Nafizal , KRISTOFFERSSON, Anna , LUNDKVIST, Johan, Rune, Michael , NIKITIDIS, Grigorios , RIPA, Lena, Elisabeth , SHAMOVSKY, Igor
IPC分类号： C07D401/06 , C07D241/28 , A61K31/497 , A61P11/00
CPC分类号： C07D401/12 , A61K31/4965 , A61K31/497 , A61K45/06 , C07D241/26 , C07D241/28 , C07D401/06
摘要： The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).
-
公开(公告)号：EP1841763A1
公开(公告)日：2007-10-10
申请号：EP05801592.6
申请日：2005-11-07
申请人： AstraZeneca AB
发明人： BENGTSSON, Malena , LARSSON, Joakim , NIKITIDIS, Grigorios , STORM, Peter , BAILEY, John Peter, AstraZeneca R & D Alderley , GRIFFEN, Edward Jolyon, AstraZeneca R & D Alderley , ARNOULD, Jean-Claude AstraZeneca Reims , BIRD, Thomas Geoffrey Colerick, AstraZeneca Reims
IPC分类号： C07D417/04 , C07D417/14 , A61K31/4439 , A61P35/00
CPC分类号： C07D417/04 , C07D417/14
摘要： The invention provides thiazole derivatives of formula (I), or pharmaceutically acceptable salts thereof in which Ring A, R1, R2 and R3 are as defined in the specification; a processes for their preparation; pharmaceutical compositions containing them; and their use in therapy, for example in the treatment of disease mediated by a PI3K enzyme and/or a mTOR kinase.
-
公开(公告)号：EP1562902B1
公开(公告)日：2006-05-03
申请号：EP03811170.4
申请日：2003-11-11
申请人： AstraZeneca AB
发明人： BLADH, Hakan , KLINGSTEDT, Tomas , LARSSON, Joakim , LAWITZ, Karolina , LEPISTÖ, Matti , LÖNN, Hans , NIKITIDIS, Grigorios
IPC分类号： C07D211/86 , C07D239/22 , A61K31/4412 , A61K31/505 , A61P29/00
CPC分类号： C07D213/64 , C07D213/82 , C07D239/557 , C07D241/24 , C07D413/12
摘要： There are provided novel compounds of formula (I) wherein R1, R4, R5, G1, G2, X, L, Y1, Y2 and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of neutrophil elastase.
-
4.发明公开
公开(公告)号：EP3292104A1
公开(公告)日：2018-03-14
申请号：EP16720441.1
申请日：2016-05-04
申请人： Astrazeneca AB
发明人： RONN, Robert , LINDH, Carl, Jonas , RINGBERG, Erik , ANDERSSON, Hanna, Birgitta, Ellinor , NILSSON, Peter , SCHAAL, Wesley, Ralph , MUNCK AF ROSENSCHÖLD, Magnus , NIKITIDIS, Antonios , NIKITIDIS, Grigorios , JOHANNESSON, Petra , TYRCHAN, Christian
IPC分类号： C07D213/74 , C07D401/08 , C07D239/42 , C07D241/20 , A61K31/44 , A61K31/4439 , A61K31/496 , A61K31/505 , A61P11/00 , A61P29/00
CPC分类号： A61K31/4965 , A61K31/44 , A61K31/4439 , A61K31/496 , A61K31/505 , C07C211/55 , C07C211/58 , C07D213/74 , C07D215/38 , C07D239/42 , C07D239/47 , C07D241/20 , C07D401/08 , C07D401/12 , C07D405/12
摘要： wherein E1, E2, E3, E4, L1, Y1, Y2, Y3, Ra and z have meanings provided in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C4 synthase is desired and/or required, and particularly in the treatment of respiratory diseases and inflammation.
-
公开(公告)号：EP1539759B1
公开(公告)日：2007-08-15
申请号：EP03788216.4
申请日：2003-08-13
申请人： AstraZeneca AB
IPC分类号： C07D471/04 , A61K31/437 , A61P37/08 , A61P11/06
CPC分类号： C07D471/04 , A61K31/437
摘要： The use of compounds of formula (I) wherein R1, R3, R10, m and Ar are as defined in the Specification and pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment or prophylaxis of diseases or conditions in which inhibition of kinase Itk activity is beneficial is disclosed. Certain novel compounds of formula (I), together with processes for their preparation, compositions containing them and their use in therapy are also disclosed.
-
公开(公告)号：EP1562902A1
公开(公告)日：2005-08-17
申请号：EP03811170.4
申请日：2003-11-11
申请人： AstraZeneca AB
发明人： BLADH, Hakan , KLINGSTEDT, Tomas , LARSSON, Joakim , LAWITZ, Karolina , LEPISTÖ, Matti , LÖNN, Hans , NIKITIDIS, Grigorios
IPC分类号： C07D211/86 , C07D239/22 , A61K31/4412 , A61K31/505 , A61P29/00
CPC分类号： C07D213/64 , C07D213/82 , C07D239/557 , C07D241/24 , C07D413/12
摘要： There are provided novel compounds of formula (I) wherein R1, R4, R5, G1, G2, X, L, Y1, Y2 and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of neutrophil elastase.
-
公开(公告)号：EP1841763B1
公开(公告)日：2010-06-30
申请号：EP05801592.6
申请日：2005-11-07
申请人： AstraZeneca AB
发明人： BENGTSSON, Malena , LARSSON, Joakim , NIKITIDIS, Grigorios , STORM, Peter , BAILEY, John Peter, AstraZeneca R & D Alderley , GRIFFEN, Edward Jolyon, AstraZeneca R & D Alderley , ARNOULD, Jean-Claude AstraZeneca Reims , BIRD, Thomas Geoffrey Colerick, AstraZeneca Reims
IPC分类号： C07D417/04 , C07D417/14 , A61K31/4439 , A61P35/00
CPC分类号： C07D417/04 , C07D417/14
摘要： The invention provides thiazole derivatives of formula (I), or pharmaceutically acceptable salts thereof in which Ring A, R1, R2 and R3 are as defined in the specification; a processes for their preparation; pharmaceutical compositions containing them; and their use in therapy, for example in the treatment of disease mediated by a PI3K enzyme and/or a mTOR kinase.
-
公开(公告)号：EP1999130A1
公开(公告)日：2008-12-10
申请号：EP07747954.1
申请日：2007-03-20
申请人： AstraZeneca AB
发明人： AUSTIN, Rupert , BONNERT, Roger , HUNT, Fraser , NIKITIDIS, Grigorios , SANGANEE, Hitesh , SJÖ, Peter , WARNER, Dan
IPC分类号： C07D471/04 , A61K31/519 , A61P29/00 , A61P37/02 , C07D519/00
CPC分类号： C07D471/04 , C07D519/00
摘要： The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a PDE 4 mediated disease state.
-
公开(公告)号：EP1539759A1
公开(公告)日：2005-06-15
申请号：EP03788216.4
申请日：2003-08-13
申请人： AstraZeneca AB
IPC分类号： C07D471/04 , A61K31/437 , A61P37/08 , A61P11/06
CPC分类号： C07D471/04 , A61K31/437
摘要： The use of compounds of formula (I) wherein R1, R3, R10, m and Ar are as defined in the Specification and pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment or prophylaxis of diseases or conditions in which inhibition of kinase Itk activity is beneficial is disclosed. Certain novel compounds of formula (I), together with processes for their preparation, compositions containing them and their use in therapy are also disclosed.
-
公开(公告)号：EP3119752A1
公开(公告)日：2017-01-25
申请号：EP15713339.8
申请日：2015-03-17
申请人： Astrazeneca AB
发明人： BERGLUND, Susanne, Elisabeth , CONNOLLY, Stephen , HEMMERLING, Martin , HOSSAIN, Nafizal , KRISTOFFERSSON, Anna , LUNDKVIST, Johan, Rune, Michael , NIKITIDIS, Grigorios , RIPA, Lena, Elisabeth , SHAMOVSKY, Igor
IPC分类号： C07D401/06 , C07D241/28 , A61K31/497 , A61P11/00
CPC分类号： C07D401/12 , A61K31/4965 , A61K31/497 , A61K45/06 , C07D241/26 , C07D241/28 , C07D401/06
摘要： The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).
摘要翻译： 本发明提供式（I）的化合物或其药学上可接受的盐; 制备这种化合物的方法; 以及在治疗ENaC介导的疾病状态（例如哮喘，CF或COPD）中使用这种化合物。
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.023 秒)
